p53, through p21 (WAF1/CIP1), Induces Cyclin D1 Synthesis

Cancer Research

Volumn 55, Issue 19, 1995, Pages 4257-4263

  Chen, Xinbin ^a   Bargonetti, Jill ^a   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; PROTEIN P21; PROTEIN P53;

ARTICLE; CELL CYCLE G1 PHASE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; TUMOR SUPPRESSOR GENE;

ANIMAL; CAMPTOTHECIN; CELL LINE; CYCLIN D1; CYCLINS; DNA DAMAGE; G1 PHASE; HUMAN; MICE; ONCOGENE PROTEINS; PROTEIN KINASES; PROTEIN P53; SUPPORT, U.S. GOV'T, NON-P.H.S.; TRANSCRIPTION, GENETIC;

EID: 0029033333     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Maltzman, W., and Czyzyk, L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4: 1689–1694, 1984.
2. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkctt, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587–597, 1992.
3. Prives, C. Doing the right thing: feedback control and p53. Curr. Biol. Cell Biol., 5: 214–218, 1993.
4. Levine, A. J. The tumor suppressor genes. Annu. Rev. Biochem., 62: 623–651, 1993.
5. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539–542, 1994.
6. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-mdm2 autoregulatory feedback loop. Genes Dev., 7: 1126–1132, 1993.
7. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Linzer, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817–825, 1993.
8. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell, 75: 805–816, 1993.
9. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701–704, 1993.
10. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574–578, 1994.
11. Li, R., Waga, S., Hannon, G. J., Beach, D., and Stillman, B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature (Lond.), 371: 534–537, 1994.
12. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323–330, 1995.
13. Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., and Livingston, D. M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 73: 487–498, 1993.
14. Sherr, C. J. Mammalian Gl cyclins. Cell, 73: 1059–1065, 1993.
15. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573–582, 1994.
16. Harvey, D. M., and Levine, A. J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev., 5: 2375–2385, 1991.
17. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romano, J. W., and Ullrich, S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Natl. Acad. Sci USA, 87: 6166–6170, 1990.
18. Chen, C., and Okayama, H. High efficiency transformation of mammalian cells by plasmid DNA. Mol. CeU. Biol., 7: 2745–2752, 1987.
19. Pan, Z.-Q., and Hurwitz, J. Reconstitution of cyclin-dependent cdc2 and cdk2 kinase activities in vitro. J. Biol. Sci., 268: 20433–20442, 1993.
20. Whyte, P., Buchkovich, K. J., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A., and Harlow, E. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (Lond.), 334: 124–129, 1988.
21. Hu, Q., Bautista, C., Edwards, G. M., Defeo-Jones, D., Jones, R. E., and Harlow, E. Antibodies specific for the retinoblastoma protein identify a family of related polypeptides. Mol. Cell. Biol., 11: 5792–5799, 1991.
22. Harlow, E., Crawford, L. V., Pim, D. C., and Williamson, N. M. Monoclonal antibodies specific for simian virus tumor antigens. J. Virol., 39: 861–869, 1981.
23. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 759: 529–534, 1986.
24. Gurney, E. G., Harris, R. O., and Fennel, J. Monoclonal antibodies against simian virus 40 T antigens: evidence for distinct subclasses of large T antigen and for similarities among nonviral antigens. J. Virol., 34: 752–763, 1980.
25. Chen, X., and Velicer, L. F. Multiple bidirectional initiations and terminations of transcription in the Marek's disease virus long repeat regions. J. Virol., 65: 2445–2451, 1990.
26. Xiong, Y., Connolly, T., Futcher, B., and Beach, D. Human D-type cyclin. Cell, 65: 691–699, 1991.
27. Marty, F. L., Piechaczyk, M., Sabrouty, S. L., Dani, C., Jeanteur, P., and Blanchard, J. M. Various rat tissues express only one major mRNA species from the glyceral-dehyde-3-phosphate dehydrogenase multigenic family. Nucleic Acids Res., 13: 1431–1442, 1985.
28. Ullrich, S. J., Mercer, W. E., and Appella, E. Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene, 7: 1635–1643, 1992.
29. Lin, D., Shields, M. T., Ullrich, S. J., Appella, E., and Mercer, W. E. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G, phase. Proc. Natl. Acad. Sci. USA, 89: 9210–9214, 1992.
30. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671–680, 1990.
31. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815–1823, 1994.
32. Zhang, H., Hannon, G. J., and Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev., 8: 1750–1758, 1994.
33. Muller, H., Lukas, J., Schneider, A., Warthoe, P., Bartek, J., Eilers, M., and Strauss, M. Cyclin Dl expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 91: 2945–2949, 1994.
34. Sherr, C. J. Gi phase progression: cycling on cue. Cell, 79: 551–555, 1994.
35. Filmus, J., Robles, A. I., Shi, W., Wong, M. J., Colombo, L. L., and Conti, C. J. Induction of cyclin Dl overexpression by activated ras. Oncogene, 9: 3627–3633, 1994.
36. Daksis, J. I., Lu, R. Y., Facchini, L. M., Marhin, W. W., and Penn, L. J. Z. Myc induces cyclin Dl expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene, 9: 3635–3645, 1994.
37. Pagano, M., Theodoras, A. M., Tarn, S. W., and Draetta, G. F. Cyclin Dl-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev., 8: 1627–1639, 1994.
38. Dulic, V., Drullinger, L. F., Lee, E., Reed, S. I., and Stein, G. H. Altered regulation of Gl cyclins in senescent human fibroblasts: accumulation of inactive cyclin E-cdk2 and cyclin D1-cdk2 complexes. Proc. Natl. Acad. Sci. USA, 90: 11034–11038, 1993.
39. Lucibello, F. C., Sewing, A., Brusselbach, S., Burger, C., and Muller, R. Deregulation of cyclins Dl and E and suppression of cdk2 and cdk4 in senescent human fibroblasts. J. Cell Sci., 105: 123–133, 1993.
40. Herber, B., Tuss, M., Beato, M., and Muller, R. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene, 9: 1295–1304, 1994.